CD8A and neoplasm: In another study, targeting METTL3 using nanoparticle-siRNA or a METTL3-specific inhibitor (STM2457) in combination with anti-PD-1 therapy reactivated CD8+ T cells, restored IFN-γ+ production, and regressed the growth of orthotopic NAFLD-HCC tumours [109,110].